modafinil has been researched along with Metabolic Diseases in 1 studies
Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.
Metabolic Diseases: Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Results of this pilot trial do not support routine use of modafinil to counteract increased weight and metabolic diseases in patients taking clozapine." | 9.15 | Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia. ( Borba, CP; Cather, C; Copeland, PM; Fan, X; Freudenreich, O; Goff, DC; Henderson, DC; Macklin, E; Wang, X, 2011) |
| "Results of this pilot trial do not support routine use of modafinil to counteract increased weight and metabolic diseases in patients taking clozapine." | 5.15 | Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia. ( Borba, CP; Cather, C; Copeland, PM; Fan, X; Freudenreich, O; Goff, DC; Henderson, DC; Macklin, E; Wang, X, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Henderson, DC | 1 |
| Freudenreich, O | 1 |
| Borba, CP | 1 |
| Wang, X | 1 |
| Copeland, PM | 1 |
| Macklin, E | 1 |
| Fan, X | 1 |
| Cather, C | 1 |
| Goff, DC | 1 |
1 trial available for modafinil and Metabolic Diseases
| Article | Year |
|---|---|
Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia.
Topics: Adult; Analysis of Variance; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cloza | 2011 |